PH23921A - Spiro-indenes and spiro-1,2-dihydro-naphthalenes for treatment of diabetic complications - Google Patents

Spiro-indenes and spiro-1,2-dihydro-naphthalenes for treatment of diabetic complications

Info

Publication number
PH23921A
PH23921A PH32003A PH32003A PH23921A PH 23921 A PH23921 A PH 23921A PH 32003 A PH32003 A PH 32003A PH 32003 A PH32003 A PH 32003A PH 23921 A PH23921 A PH 23921A
Authority
PH
Philippines
Prior art keywords
spiro
indenes
naphthalenes
dihydro
treatment
Prior art date
Application number
PH32003A
Other languages
English (en)
Inventor
Christopher Andrew Lipinski
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of PH23921A publication Critical patent/PH23921A/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D233/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/72Two oxygen atoms, e.g. hydantoin
    • C07D233/80Two oxygen atoms, e.g. hydantoin with hetero atoms or acyl radicals directly attached to ring nitrogen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D235/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • A61P27/12Ophthalmic agents for cataracts
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D263/00Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/52Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D277/00Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/60Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Ophthalmology & Optometry (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
PH32003A 1984-03-23 1985-03-19 Spiro-indenes and spiro-1,2-dihydro-naphthalenes for treatment of diabetic complications PH23921A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US59301284A 1984-03-23 1984-03-23

Publications (1)

Publication Number Publication Date
PH23921A true PH23921A (en) 1990-01-23

Family

ID=24372993

Family Applications (1)

Application Number Title Priority Date Filing Date
PH32003A PH23921A (en) 1984-03-23 1985-03-19 Spiro-indenes and spiro-1,2-dihydro-naphthalenes for treatment of diabetic complications

Country Status (15)

Country Link
EP (1) EP0159143B1 (en, 2012)
JP (1) JPS60209572A (en, 2012)
KR (1) KR850006188A (en, 2012)
AU (1) AU563668B2 (en, 2012)
CA (1) CA1244443A (en, 2012)
DE (1) DE3561198D1 (en, 2012)
DK (1) DK131885A (en, 2012)
ES (1) ES8606295A1 (en, 2012)
FI (1) FI851170A7 (en, 2012)
GR (1) GR850704B (en, 2012)
HU (1) HU195783B (en, 2012)
IL (1) IL74667A (en, 2012)
PH (1) PH23921A (en, 2012)
PL (1) PL145198B1 (en, 2012)
PT (1) PT80145B (en, 2012)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4575507A (en) * 1985-05-29 1986-03-11 Pfizer Inc. Spiro-imidazolidines as aldose reductase inhibitors and their pharmaceutical use
GB2355264A (en) 1999-09-30 2001-04-18 Merck & Co Inc Spirohydantoin derivatives useful as alpha 1a adrenoceptor antagonists
EP1605936B1 (en) * 2003-03-14 2011-07-20 Merck Sharp & Dohme Corp. Aryl spirohydantoin cgrp receptor antagonists
CA2579850A1 (en) * 2004-09-13 2006-03-23 Merck & Co., Inc. Tricyclic anilide spirohydantoin cgrp receptor antagonists
US8071770B2 (en) 2005-11-18 2011-12-06 Merck Sharp & Dohme Corp. Spirohydantoin aryl CGRP receptor antagonists
CN111732545B (zh) * 2020-06-08 2023-03-10 华侨大学 一种2,3-二氢螺[咪唑-4,1′-茚]类化合物及其制备方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4117230A (en) * 1976-10-18 1978-09-26 Pfizer Inc. Hydantoin derivatives as therapeutic agents
US4130714A (en) * 1977-05-23 1978-12-19 Pfizer Inc. Hydantoin therapeutic agents
US4181729A (en) * 1979-03-21 1980-01-01 Pfizer Inc. Phenyl or phenoxy substituted spiro-imidazolidinedione derivatives
US4226875A (en) * 1979-04-02 1980-10-07 Pfizer Inc. Novel spiro-oxazolidinediones
ES8400116A1 (es) * 1981-10-13 1983-10-16 Pfizer "un procedimiento por analogia para la preparacion de derivados de espiro-oxindol-oxazolidindiona".
ZA832679B (en) * 1982-05-07 1983-12-28 Ici Plc Indoline derivatives
US4556670A (en) * 1982-12-06 1985-12-03 Pfizer Inc. Spiro-3-hetero-azolones for treatment of diabetic complications

Also Published As

Publication number Publication date
EP0159143A1 (en) 1985-10-23
CA1244443A (en) 1988-11-08
GR850704B (en, 2012) 1985-07-19
FI851170L (fi) 1985-09-24
PL145198B1 (en) 1988-08-31
PT80145A (en) 1985-04-01
FI851170A0 (fi) 1985-03-22
DK131885A (da) 1985-09-24
AU563668B2 (en) 1987-07-16
AU4025185A (en) 1985-09-26
JPS60209572A (ja) 1985-10-22
DK131885D0 (da) 1985-03-22
ES8606295A1 (es) 1986-04-16
IL74667A0 (en) 1985-06-30
HUT37603A (en) 1986-01-23
EP0159143B1 (en) 1987-12-16
PT80145B (en) 1987-03-23
HU195783B (en) 1988-07-28
DE3561198D1 (en) 1988-01-28
IL74667A (en) 1988-12-30
FI851170A7 (fi) 1985-09-24
ES541450A0 (es) 1986-04-16
PL252487A1 (en) 1985-10-08
KR850006188A (ko) 1985-10-02

Similar Documents

Publication Publication Date Title
PL254699A1 (en) Tobacco treatment method
AU580820B2 (en) Treatment of obesity
EP0150914A3 (en) Skin treatment composition
GB8614300D0 (en) Treatment of tobacco
GB8419516D0 (en) Treatment
GB8419515D0 (en) Treatment
GB8412049D0 (en) Treatment
GB2198942B (en) Therapeutic composition for diabetic complications
GB8501959D0 (en) Treatment of tobacco
AU581672B2 (en) Novel treatment
DE3561198D1 (en) Spiro-indenes and spiro-1,2-dihydro-naphthalenes for treatment of diabetic complications
DE3379043D1 (en) Spiro-3-hetero-azolones for treatment of diabetic complications
GB8521996D0 (en) Treatment of structure
ZA839023B (en) Spiro-3-hetero-azolones for treatment of diabetic complications
AU538406B3 (en) Hair treatment
GB8421539D0 (en) Treatment of tobacco
GB8401863D0 (en) Treatment of bromidrosis
ZA829106B (en) Treatment for diabetic complications
GB8504905D0 (en) Treatment of glaucoma
GB8400462D0 (en) Skin treatment composition
GB8408174D0 (en) Skin treatment composition
GB8400461D0 (en) Skin treatment composition
GB8431970D0 (en) Treatment of structure
GB8510810D0 (en) Treatment of diabetes mellitus
GB8419514D0 (en) Treatment